Filgrastim

Generic Name
Filgrastim
Brand Names
Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
Drug Type
Biotech
Chemical Formula
-
CAS Number
121181-53-1
Unique Ingredient Identifier
PVI5M0M1GW
Background

Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...

Indication

Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...

Associated Conditions
Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
Associated Therapies
Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Clinical Trials
Related News

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

First Posted Date
2017-06-09
Last Posted Date
2019-08-20
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
48
Registration Number
NCT03181815
Locations
🇨🇳

Liang Wang, Guangzhou, Guangdong, China

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2017-05-23
Last Posted Date
2024-05-29
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
206
Registration Number
NCT03164057
Locations
🇺🇸

Rady Children's Hospital and Health Center, San Diego, California, United States

🇺🇸

Children's Hospital of Central California, Madera, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

and more 7 locations

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

First Posted Date
2017-05-10
Last Posted Date
2024-03-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT03147612
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Auto Stem Cell Transplant for Lymphoma Patients

First Posted Date
2017-04-24
Last Posted Date
2024-11-04
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
150
Registration Number
NCT03125642
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

First Posted Date
2017-03-13
Last Posted Date
2024-08-07
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
57
Registration Number
NCT03077542
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients

First Posted Date
2017-02-07
Last Posted Date
2017-02-07
Lead Sponsor
Shandong University
Target Recruit Count
120
Registration Number
NCT03045627
Locations
🇨🇳

Qilu hospital, Shandong University, Jinan, Shandong, China

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants

Phase 3
Terminated
Conditions
Healthy Participants
Interventions
Drug: Tbo-filgrastim
First Posted Date
2017-01-23
Last Posted Date
2022-12-13
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
1
Registration Number
NCT03029000
Locations
🇺🇸

Teva Investigational Site 14024, San Antonio, Texas, United States

🇺🇸

Teva Investigational Site 14025, La Jolla, California, United States

🇺🇸

Teva Investigational Site 14030, Cincinnati, Ohio, United States

and more 6 locations

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

First Posted Date
2017-01-02
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
475
Registration Number
NCT03007147
Locations
🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 224 locations

Neuroregenerative Potential of Intravenous G-CSF and Autologous Peripheral Blood Stem Cells

First Posted Date
2016-12-06
Last Posted Date
2016-12-07
Lead Sponsor
Hanyang University Seoul Hospital
Target Recruit Count
57
Registration Number
NCT02983708

G-CSF Plus NAC In Severe Alcoholic Hepatitis

First Posted Date
2016-11-22
Last Posted Date
2017-09-19
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
60
Registration Number
NCT02971306
Locations
🇮🇳

Dept of Hepatology, PGIMER, Chandigarh, India

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy